Geranylgeranylacetone did not significantly improve diastolic function (E/e' difference -0.24, p=0.46) or endothelial function (RHI difference -0.02, p=0.92) vs placebo in patients with HFpEF.
RCT (n=43)
Double-blind
1:1
Does geranylgeranylacetone improve diastolic function and reactive hyperaemia index in patients with HFpEF?
In a phase 2 crossover trial, geranylgeranylacetone failed to improve diastolic or endothelial function in patients with HFpEF.
Effect estimate: Mean difference -0.24 (E/e') and -0.02 (RHI) (95% CI -0.90 to 0.41 (E/e') and -0.36 to 0.33 (RHI))
p-value: p=0.46 (E/e') and 0.92 (RHI)
AIMS: Heart failure with preserved ejection fraction (HFpEF) is a major healthcare burden with limited treatment options. Geranylgeranylacetone (GGA) has been shown to improve myocardial compliance and endothelial function in preclinical models. Given the mechanistic profile of GGA and established safety as an over-the-counter drug in Asia, we performed a phase 2 clinical trial in patients with HFpEF. METHODS AND RESULTS: GLADIATOR-HFpEF (NCT05672134, EudraCT2022-000655-36-NL) is a phase 2, double-blind, randomized, placebo-controlled, crossover trial. Patients were randomized 1:1 to GGA or placebo and treated for 3 months with a washout-period of 6 weeks. The dual primary endpoints were diastolic function (E/e') and reactive hyperaemia index (RHI). Secondary endpoints were renal haemodynamic measurements; measured glomerular filtration rate and effective renal plasma flow, New York Heart Association class and 6-min walking test distance, cardiac biomarkers (N-terminal pro-B-type natriuretic peptide NT-proBNP, high-sensitivity C-reactive protein), quality of life and laser speckle contrast analysis. Between March 2023 and December 2023, 43 patients were randomized and 39 were included in the per-protocol analysis. The cohort consisted of 28 women (72%), mean left ventricular ejection fraction was 59% and median NT-proBNP was 238 ng/L. There were no significant differences in the primary outcomes; E/e' (-0.24 -0.90-0.41, p = 0.46) and RHI (-0.02 -0.36-0.33, p = 0.92). We found a decrease in BSA-adjusted ERPF (-29.62-57.52;1.71, p = 0.038) and BSA-adjusted RBF (-50.20 -95.80; -4.61, p = 0.032). There were no significant differences in safety outcomes. CONCLUSIONS: Geranylgeranylacetone, a drug that showed promising effects on myocardial relaxation and endothelial function in preclinical studies, had no effects on diastolic function, endothelial function and exercise capacity in patients with HFpEF. GGA reduced effective renal plasma flow and renal blood flow. There were no differences in safety outcomes between GGA and placebo.
Nassiri et al. (Mon,) conducted a rct in Heart failure with preserved ejection fraction (HFpEF) (n=43). Geranylgeranylacetone (GGA) vs. Placebo was evaluated on Diastolic function (E/e') and reactive hyperaemia index (RHI) (Mean difference -0.24 (E/e') and -0.02 (RHI), 95% CI -0.90 to 0.41 (E/e') and -0.36 to 0.33 (RHI), p=0.46 (E/e') and 0.92 (RHI)). Geranylgeranylacetone did not significantly improve diastolic function (E/e' difference -0.24, p=0.46) or endothelial function (RHI difference -0.02, p=0.92) vs placebo in patients with HFpEF.